Randox Laboratories (India) Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 11-01-2025
- Paid Up Capital ₹ 9.87 Cr
as on 11-01-2025
- Company Age 20 Year, 19 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.00 M
as on 11-01-2025
- Revenue 31.19%
(FY 2022)
- Profit -193.98%
(FY 2022)
- Ebitda -50.14%
(FY 2022)
- Net Worth -102.43%
(FY 2022)
- Total Assets -15.49%
(FY 2022)
About Randox Laboratories (India)
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.87 Cr.
The company currently has active open charges totaling ₹8.00 M.
Stephen Fitzgerald, Richard Kelly, and Umesh serve as directors at the Company.
- CIN/LLPIN
U24230KA2004PTC070372
- Company No.
070372
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Dec 2004
- Date of AGM
14 Nov 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Randox Laboratories (India) Private Limited offer?
Randox Laboratories (India) Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Biochemistry Analyzer.
Who are the key members and board of directors at Randox Laboratories (India)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Stephen Fitzgerald  | Director | 28-Dec-2004 | Current |
| Richard Kelly | Director | 28-Jan-2019 | Current |
Umesh  | Director | 08-Aug-2022 | Current |
Financial Performance of Randox Laboratories (India).
Randox Laboratories (India) Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 31.19% increase. The company also saw a substantial fall in profitability, with a 193.98% decrease in profit. The company's net worth observed a substantial decline by a decrease of 102.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Randox Laboratories (India)?
In 2022, Randox Laboratories (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Citi Bank N.A. Creation Date: 06 Jun 2014 | ₹8.00 M | Open |
How Many Employees Work at Randox Laboratories (India)?
Randox Laboratories (India) has a workforce of 114 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Randox Laboratories (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Randox Laboratories (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
